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INTELLECTUAL PROPERTY (IP): THE CONCEPT 
• Intellectual Property [IP] is all about the results of human 
creativity. 
 
• IP’s subject matter is formed from new ideas generated by 
human beings. 
 
• Their application to human needs can be of considerable 
benefit to mankind 
. 
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INTELLECTUAL PROPERTY (IP): THE CONCEPT  
cont. 
• Protecting the development and application 
of new ideas assists in the realization of the 
benefits that derive from these ideas.   
 
• INTELLECTUAL PROPERTY LAW IS THE 
MEANS USED TO PROVIDE THIS 
PROTECTION. 
 
• So it is about the rules protecting 
COPYRIGHT, PATENTS, TRADEMARKS, 
INDUSTRIAL DESIGNS AND 
GEOGRAPHICAL INDICATIONS 
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QATAR and IP 
• The Agreement on Trade-Related Aspects of Intellectual Property Rights 
(TRIPS) under the umbrella of the World Trade Organization (WTO) 
 
 
• Is an international legal agreement between all the member nations of the 
WTO (Qatar has been a member of the WTO since Jan. 13, 1996). It sets 
down minimum standards for the regulation by national governments of 
many forms of IP as applied to nationals of other WTO member nations. 
 
 
• Qatar is also member of the World Intellectual Property Organization 
(WIPO) 
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WIPO 
• WIPO was established in 1967 and Qatar has been a member of WIPO since 
September 1976. 
 
• WIPO was created to:  
 
1. promote the protection of IP throughout the world by co-operation among 
States and, where appropriate, in collaboration with any other international 
organizations; and 
 
2. to ensure administrative co-operation among the intellectual  
     property Unions. 
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QATAR’S OTHER MEMBERSHIPS 
• Of the Paris Convention for the Protection of Industrial Property 
Convention and of the Berne Convention for the protection of Literary 
and Artistic Works  since July 2000. 
 
 
• Of the Patent Cooperation Treaty (the PCT), since August 3, 2011 
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Patent Cooperation Treaty  
cont. 
The Patent Cooperation Treaty (PCT) makes it possible to seek 
patent protection for an invention simultaneously in each of a large 
number of countries by filing an "international" patent application.  
 
Such an application may be filed by anyone who is a national or 
resident of a PCT Contracting State. It may generally be filed with the 
national patent office of the Contracting State of which the applicant 
is a national or resident or, at the applicant's option, with the 
International Bureau of WIPO in Geneva. 
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INTELLECTUAL PROPERTY LAWS OF  
QATAR 
1. Law No.7 of 2002 on the Protection of Copyright and Neighbouring 
Rights. 
2. Law No. 9 of 2002 on Trade Marks, Trade Data, Trade Names, 
Geographical Indications and Industrial Designs. 
3. Law No. 5 of 2005 on the Protection of Trade Secrets. 
4. Law No. 6 of 2005 Relating to the Protection of Layout Designs of 
Integrated Circuits.  
5. Law No. 30 of 2006 concerning Patents.  
6.  Legislation concerning plant variety protection is still under 
consideration. 
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TECHNOLOGY TRANSFER (TT) IN THE  
PHARMACEUTICAL INDUSTRY 
TT IN THE PHARMA INDUSTRY REFERS TO THE PROCESSES OF 
SUCCESFFUL PROGRESS OF DRUG DISCOVERY TO PRODUCT 
DEVELOPMENT, CLINICAL TRIALS AND ULTIMATELY FULL SCALE 
COMMERCIALIZATION 
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FACETS OF TECHNOLOGY TRANSFER 
IN THE 
 PHARMA INDUSTRY 
1. Government labs to private sector firms 
 
2. Between private sector firms of the same country 
 
3. Between private sector firms of different countries 
 
4. From academia to private sector firms 
 
5. Academia, Government and industry collaborations 
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TECHNOLOGY TRANSFER  
cont.  
• For TT to be successful there needs to be a supportive business 
and scientific environment in the recipient country, and that 
environment should include skilled workers, economic and 
political stability, supportive regulatory environment, market size 
and potential and a well developed national infrastructure of 
natural resources and transport. 
   
• Transparent and efficient regulation – Pharmaceuticals are 
necessarily a high regulated industry, the regulatory function must 
be efficient and transparent for technology transfer to be 
economically viable. 
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THE EXAMPLE OF IRELAND 
• Ireland is the 7th largest exporter of medicinal and pharmaceutical 
products in the world (2014). 
 
• Ireland is now the largest net exporter of pharmaceuticals in the EU 
accounting for over 50% of all exports from the country. In 2014 the 
sector exported products to the value of €64 billion. 
 
• Approximately 120 overseas companies have plants in Ireland. 
 
• Ireland has 9 of the top 10 largest pharmaceutical companies in the 
world with operations throughout the country. 
 
• The sector contributes more than €1 billion in corporation tax  
     to the Irish Exchequer annually. 
 
• The international research-based pharmaceutical industry  
     has invested over €7 billion in the last ten years  
      in Ireland. 14 
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THE EXAMPLE OF IRELAND 
cont. 
INVESTMENT INCENTIVES 
 
• Ireland’s intellectual property laws provide companies with generous 
incentives to innovate. In conjunction, the Irish tax system which offers 
a highly competitive corporate tax rate of 12.5 % is a major incentive. 
No tax is paid on earnings from intellectual property where the 
underlying R&D work was carried out in Ireland. 
 
 
• Ireland recently introduced a new R&D Tax Credit, designed to 
encourage companies to undertake new and/or additional R&D  
    activity in Ireland. It covers wages, elated overheads,  
    plant/machinery and buildings. Stamp duty on intellectual  
    property rights has been abolished. 
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THE EXAMPLE OF IRELAND cont. 
• 46% of pharma employees are third-level graduates. 
 
• 30% year on year growth in employment since 2008. 
 
• 25% of all PhD researchers in Irish industry are employed in the sector. 
 
• In 2008, 2 out of every 5 pharmaceutical jobs created in Europe were in 
Ireland. 
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